舌癌治療モデルにおける免疫療法の応用に関する実験的研究 : 宿主免疫能と細胞表面酵素阻害物質について
スポンサーリンク
概要
- 論文の詳細を見る
The host immunity of the experimental lingual cancer system of golden hamster which is induced by 1.0% DMBA aceton soL, was investigated. At each stage of the carcinogenesis, cellular immunity (CI) was assayed by contact hypersensitivity test and humoral immunity (HI) was assayed by direct plaque forming cell test. The results are as follows, 1) CI was suppressed from 7th week and extremely suppressed from 11 th week through 20th week 2) HI was once enhanced from 3rd week through 5th week, but from 7th week suppressed and extremely suppressed from 11th week through 20th week. Next, the effect of bestatin (BS). an immunomodulator, on this experimental lingual cancer system was investigated as follows. 1) With carcinogenic procedure. BS was administered ip. in doses of 2. 5mg/kg and 5. Omg/kg. 3 times a week for 11 weeks. 2) From the 12th through the 15th week, 100mg/kg of FT 207(FT), 2.5mg/kg of BS or 100mg/kg FT+2.5mg/kg BS was administered ip. in 6 doses per week. Each of these treatment regimens was accompanied by a control group which was administered only 0.5ml of physiological saline solution. The results of these experiments were as follows. 1) BS, administered from the early stage of the carcinogenic process, showed carcinogenesis inhibitory action and a tumor growth inhibitory effect, both of which were thought to be due to BS's effects on the host's immune functions. 2) Once carcinogenesis had been achieved (from the 12th week), BS given alone was not found to have much effect on the cancer growth. When BS was administered together with FT, there was early inhibition of FT's masking activity toward 5FU. In addition, this combination showed a significantly enhanced tumor growth inhibitory effect in comparison with FT alone, and BS was able to prevent the immunosuppressive activity of FT. The full report presents the details of these findings concerning the host immunity and the effects of BS on experimental lingual cancer.
著者
関連論文
- 舌癌治療モデルにおける免疫療法の応用に関する実験的研究 : 宿主免疫能と細胞表面酵素阻害物質について
- DMBA誘導ハムスタ-舌腫瘍の形成と治療に関する研究-4-ハムスタ-舌腫瘍に及ぼすFT207と細胞表面酵素阻害物質(ベスタチン)併用の影響について
- 舌の小腫瘤により診断が確定した原発性アミロイドーシスの1症例
- A case of neurilemmoma in the infratemporal fossa.
- Gingival ulcer after tooth extraction as a initital symptom of T cell chronic lymphocytic leukemia(T-CLL).